Arbutus Biopharma (NASDAQ:ABUS) was upgraded by equities research analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research report issued to clients and investors on Thursday, December 21st.
A number of other brokerages have also recently commented on ABUS. JMP Securities reissued an “outperform” rating and issued a $13.00 price objective (up from $12.00) on shares of Arbutus Biopharma in a research note on Wednesday, October 4th. ValuEngine raised shares of Arbutus Biopharma from a “sell” rating to a “hold” rating in a research note on Thursday, September 21st. Wedbush reaffirmed an “outperform” rating and set a $9.00 price target on shares of Arbutus Biopharma in a research note on Wednesday, September 20th. Leerink Swann reaffirmed a “market perform” rating and set a $5.00 price target (up from $4.00) on shares of Arbutus Biopharma in a research note on Tuesday, November 7th. Finally, Zacks Investment Research raised shares of Arbutus Biopharma from a “sell” rating to a “hold” rating in a research note on Tuesday, November 7th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and five have given a buy rating to the company’s stock. Arbutus Biopharma has an average rating of “Hold” and a consensus target price of $12.50.
Arbutus Biopharma (NASDAQ:ABUS) opened at $5.10 on Thursday. The firm has a market cap of $280.77, a price-to-earnings ratio of -1.02 and a beta of 1.07. Arbutus Biopharma has a 52 week low of $2.35 and a 52 week high of $8.25. The company has a debt-to-equity ratio of 0.08, a quick ratio of 11.03 and a current ratio of 11.03.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Vanguard Group Inc. lifted its holdings in Arbutus Biopharma by 2.7% during the 2nd quarter. Vanguard Group Inc. now owns 77,413 shares of the biopharmaceutical company’s stock valued at $279,000 after buying an additional 2,035 shares in the last quarter. OxFORD Asset Management LLP raised its holdings in shares of Arbutus Biopharma by 89.9% in the 2nd quarter. OxFORD Asset Management LLP now owns 83,310 shares of the biopharmaceutical company’s stock valued at $300,000 after purchasing an additional 39,436 shares in the last quarter. RTW Investments LP raised its holdings in shares of Arbutus Biopharma by 1.1% in the 3rd quarter. RTW Investments LP now owns 5,266,280 shares of the biopharmaceutical company’s stock valued at $32,651,000 after purchasing an additional 56,457 shares in the last quarter. Renaissance Technologies LLC raised its holdings in shares of Arbutus Biopharma by 785.1% in the 1st quarter. Renaissance Technologies LLC now owns 124,573 shares of the biopharmaceutical company’s stock valued at $405,000 after purchasing an additional 110,499 shares in the last quarter. Finally, Victory Capital Management Inc. bought a new stake in shares of Arbutus Biopharma in the 2nd quarter valued at about $478,000. Institutional investors own 59.97% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Arbutus Biopharma (ABUS) Upgraded to Sell at BidaskClub” was originally reported by The Lincolnian Online and is owned by of The Lincolnian Online. If you are reading this report on another domain, it was stolen and republished in violation of U.S. and international copyright & trademark law. The original version of this report can be accessed at https://www.thelincolnianonline.com/2018/01/14/arbutus-biopharma-abus-upgraded-by-bidaskclub-to-sell-3-updated-updated.html.
About Arbutus Biopharma
Arbutus Biopharma Corporation, formerly Tekmira Pharmaceuticals Corporation, is a therapeutic solutions company. The Company is engaged in discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection (HBV), a disease of the liver caused by the hepatitis B virus (HBV).
Receive News & Ratings for Arbutus Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arbutus Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.